Genelux Begins Clinical Studies of Virotherapy in Ovarian and Other Cancers

Genelux Begins Clinical Studies of Virotherapy in Ovarian and Other Cancers
Genelux Corporation announced the start of two Phase 1b, dose-escalation studies of its leading investigational oncolytic virotherapy, GL-ONC1, in ovarian and other cancers. The trials are being conducted at the Florida Hospital Cancer Institute (FHCI) in Orlando and the Moores Cancer Center at UC San Diego Health, and both sites are now recruiting patients. GL-ONC1 is a genetically stable oncolytic virus designed to locate, enter, colonize and destroy cancer cells without harming healthy tissues or organs. The therapy is based on the vaccinia virus (Lister strain), which was used safely in millions of people as the vaccine against smallpox. Genelux has modified this virus to increase its anti-tumor activity, tumor selectivity and safety without limiting its ability to replicate in cancer cells. Thomas Zindrick, president and CEO of Genelux, said in a press release, “The initiation of these two trials with leading U.S. medical institutions is a significant milestone in the clinical advancement of GL-ONC1 and will provide Genelux with significant near-term data milestones. Following positive results in four completed clinical trials, including the two Phase 1 trials in head and neck cancer and mesothelioma presented at the 2015 ASCO Annual Meeting, which confirmed the safety and favo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *